Cutting protein into signal-sized pieces

Fish heads, skins and bones are not uniform waste; they are connective tissue — protein assembled into load-bearing structures. The marine-peptide industry exists because proteins can be cut in a controlled way, and because some of the resulting fragments are small enough to survive digestion and enter the bloodstream intact.

Hydrolysis is controlled degradation

Enzymatic hydrolysis uses proteases to clip peptide bonds: endoproteases cut inside the chain and determine fragment length, exoproteases trim the ends. The central control variable is the degree of hydrolysis — how many bonds are broken. Cut too little and the protein stays a bulky, poorly absorbed polymer; cut too much and the hydrolysate turns bitter, because short peptides with hydrophobic ends taste bitter to human receptors. Between those poles lies the product space, and membrane ultrafiltration is what industrializes it: a cut-off membrane sorts the hydrolysate by molecular weight, so “collagen peptides under 2 kilodaltons” is not marketing but a fraction actually separated by physics. Enzyme choice also shapes function, since each protease recognizes specific sequence contexts — this is why the same skin yields different products under different enzyme systems.

What collagen contributes

Collagen is not an ordinary protein: three chains wind into a triple helix stabilized by glycine every third position and by cross-links. Hydrolysis only works after that helix is unwound — heat does it, turning collagen into gelatin — after which proteases cut the relaxed chains into short peptides. Fish skin is nearly pure type I collagen, the same type as human skin and bone, which is the raw logic of the marine version’s popularity. Absorption is the best-established link in the whole chain: di- and tri-peptides cross the gut wall through dedicated peptide transporters, and hydroxyproline-containing collagen fragments are demonstrably detectable in blood after ingestion. That part is physiology, not promise.

Where the evidence stands

Beyond absorption, claims stratify sharply. The strongest case is skin: several controlled trials find modest improvements in hydration and elasticity after oral collagen peptides, though the mechanism is still argued — the fragments may act as signaling molecules in fibroblasts or merely supply an enriched amino-acid substrate, and the debate is unresolved. Blood-pressure effects rest on ACE-inhibitory peptides, which block the angiotensin-converting enzyme in vitro impressively; in vivo the same peptides are digested further, doses in food are small, and measured effects in trials are modest and inconsistent. Antioxidant claims are the weakest: radical-scavenging assays in a test tube say little about what a peptide does inside tissues, and the leap from assay to “anti-ageing” is marketing. The honest summary is that the chemistry, the cut-offs and the absorption are solid; the clinical effects are real but small; and most product language spends far beyond what either supports. What would have to be shown for the language to catch up is the subject of health-claim substantiation.